Pressure on results from substantial R&D expenses and an R&D-led business model
First written in FY2016. 15 of 36 entries say "Mitigated", first in FY2019-Q3. Latest entry: 2026-08-07.
OncoTherapy Science moved to the "Worse" side of this theme in 2026, 5 years after the typical company in this theme (2021).
The whole theme swung hardest in 2026: 7 of 12 companies on the "Worse" side.
2 other companies' latest entry also says "Mitigated".
- 2026-08-07MitigatedEarnings
「In addition, mainly due to the recognition of research and development expenses from the continued basic research on drug candidates and drug discovery research, expenses associated with progress in clinical development in the three areas of small-molecule drugs, cancer peptide vaccines and antibody drugs, and the recognition of cost of sales related to the cancer precision medicine business, consolidated operating loss was ¥285 million, compared with a loss of ¥303 million in the previous period.」
Research and development expenses declined from ¥182 million in the same period of the previous year to ¥163 million, while consolidated operating loss narrowed from ¥303 million to ¥285 million. However, the cost burden from the research-led strategy and operating loss continue. - FY2026WorsenedAnnual report
「As an R&D-oriented company, the group recorded R&D expenses of ¥534 million in the current consolidated fiscal year.」
R&D expenses increased from ¥491 million in the previous fiscal year to ¥534 million, while the consolidated operating loss widened from ¥797 million to ¥810 million. Cost and loss pressure from the R&D-led business model intensified. - FY2026-H1R&D expenses increased; operating loss narrowedAnnual report
「Total R&D expenses for the interim consolidated accounting period were ¥286 million.」
R&D expenses increased from ¥262 million in the same period of the previous year to ¥286 million, while the consolidated operating loss narrowed from ¥531 million to ¥475 million. The cost burden from the R&D-led business model continued. - FY2025MitigatedAnnual report
「As an R&D-oriented company, the group recorded R&D expenses of ¥491 million in the current consolidated fiscal year.」
R&D expenses declined from ¥678 million in the previous fiscal year to ¥491 million, and the consolidated operating loss narrowed from ¥1,120 million to ¥798 million. The cost burden from the R&D-led business model continued. - FY2025-H1MitigatedAnnual report
「Total R&D expenses for the interim consolidated accounting period were ¥262 million.」
R&D expenses declined from ¥405.761 million in the same period of the previous year to ¥262.376 million, and the consolidated operating loss narrowed from ¥694 million to ¥531 million. The cost burden from R&D, clinical development and other activities continued. - FY2024-Q3WorsenedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and recognition of cost of sales related to the precision oncology business. The consolidated operating loss was ¥972 million (loss of ¥904 million in the previous period).」
Amid the continued cost burden from R&D, clinical development and other activities, the consolidated operating loss widened from ¥904 million in the same period of the previous year to ¥972 million. R&D expenses were ¥538 million. - FY2024-Q2WorsenedAnnual report
「Total R&D expenses for the first half of the current consolidated cumulative period were ¥405 million. In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and recognition of cost of sales related to the precision oncology business. The consolidated operating loss was ¥694 million (loss of ¥618 million in the previous period).」
R&D expenses were ¥405.761 million, up from ¥404.229 million in the same period of the previous year. The consolidated operating loss also widened from ¥618 million to ¥694 million, and earnings pressure from R&D, clinical development and other activities intensified. - FY2024-Q1WorsenedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and recognition of cost of sales related to the precision oncology business. The consolidated operating loss was ¥386 million (loss of ¥307 million in the previous period).」
Amid the continued cost burden from R&D, clinical development and other activities, the operating loss widened from ¥307 million in the same period of the previous year to ¥386 million. R&D expenses were ¥234 million, up from ¥233 million in the same period of the previous year. - FY2023MitigatedAnnual report
「As an R&D-oriented company, the group recorded ¥716 million in the fiscal year ended March 2023 and intends to continue pursuing clinical development proactively.」
R&D expenses declined from ¥1,730 million in the previous fiscal year to ¥716 million, and the consolidated operating loss narrowed from ¥2,052 million to ¥1,106 million. The cost burden from the R&D-led business model continued. - FY2023-Q3MitigatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and R&D expenses related to the precision oncology business. The consolidated operating loss was ¥904 million (loss of ¥1,710 million in the previous period).」
The cost burden from R&D and clinical development continued, but R&D expenses were ¥562 million and the operating loss narrowed from ¥1,710 million in the same period of the previous year to ¥905 million. - FY2023-Q2MitigatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and R&D expenses related to the precision oncology business. The consolidated operating loss was ¥618 million (loss of ¥948 million in the previous period).」
The cost burden from R&D and clinical development continued, but R&D expenses were ¥404 million and the operating loss narrowed from ¥948 million in the same period of the previous year to ¥618 million. - FY2023-Q1MitigatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were R&D expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and recognition of cost of sales related to the precision oncology business. The consolidated operating loss was ¥307 million (loss of ¥571 million in the previous period).」
R&D expenses were ¥233 million and the consolidated operating loss was ¥307 million, narrowing from the operating loss of ¥571 million in the same period of the previous year. The cost burden associated with R&D and clinical development continued. - FY2022WorsenedAnnual report
「As an R&D-oriented company, the group recorded ¥1,730 million in the fiscal year ended March 2022 and intends to continue pursuing clinical development proactively.」
R&D expenses increased to ¥1,730 million from ¥1,375 million in the previous consolidated fiscal year. The consolidated operating loss also widened to ¥2,052 million from ¥1,637 million in the previous fiscal year. - FY2022-Q3WorsenedAnnual report
「Total R&D expenses for the first 3 quarters of the current consolidated cumulative period were ¥1,380 million.」
R&D expenses increased from ¥972 million in the same period of the previous year to ¥1,380 million, and the consolidated operating loss widened from ¥1,266 million to ¥1,710 million. Cost and loss pressure from the R&D-led business model intensified. - FY2022-Q2WorsenedAnnual report
「Total R&D expenses for the first half of the current consolidated cumulative period were ¥747 million.」
R&D expenses increased from ¥641 million in the same period of the previous year to ¥747 million, and the consolidated operating loss widened from ¥838 million to ¥948 million. Cost and loss pressure from the R&D-led business model increased, as shown by the figures. - FY2022-Q1WorsenedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥467 million.」
R&D expenses increased from ¥291 million in the same period of the previous year to ¥467 million, and the consolidated operating loss widened from ¥399 million to ¥571 million. Cost and loss pressure from the R&D-led business model increased, as shown by the figures. - FY2021-Q3MitigatedAnnual report
「Total R&D expenses for the first 3 quarters of the current consolidated cumulative period were ¥972 million.」
R&D expenses declined from ¥1,312 million in the same period of the previous year to ¥972 million, and the consolidated operating loss narrowed from ¥1,735 million to ¥1,266 million. The cost burden from the R&D-led business model continued. - FY2021-Q2MitigatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and R&D expenses related to the precision oncology business. The consolidated operating loss was ¥838 million (loss of ¥1,218 million in the previous period).」
R&D and clinical development expenses continued to be incurred, but the consolidated operating loss narrowed from the same period of the previous year. R&D expenses also declined from ¥921 million to ¥641 million. - FY2021-Q1MitigatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and R&D expenses related to the precision oncology business. The consolidated operating loss was ¥399 million (loss of ¥617 million in the previous period).」
R&D and clinical development expenses continued to be incurred, but the consolidated operating loss narrowed from ¥617 million in the same period of the previous year to ¥399 million. - FY2020MitigatedAnnual report
「As an R&D-oriented company, the group recorded ¥1,742 million in the fiscal year ended March 2020 and intends to continue pursuing clinical development proactively.」
R&D expenses were ¥1,742 million, down from ¥2,826 million in the previous fiscal year. While the consolidated operating loss also narrowed from ¥2,953 million to ¥2,189 million, the cost burden from the R&D-led business model continued. - FY2020-Q3MitigatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and R&D expenses related to the precision oncology business. The consolidated operating loss was ¥1,735 million (loss of ¥2,146 million in the previous period).」
R&D expenses were ¥1,312 million and the operating loss was ¥1,735 million, narrowing from the operating loss of ¥2,146 million in the same period of the previous year. R&D and clinical development expenses continued to be incurred. - FY2020-Q2MitigatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and R&D expenses related to the precision oncology business. The consolidated operating loss was ¥1,218 million (loss of ¥1,725 million in the previous period).」
R&D and clinical development expenses continued to be incurred, while R&D expenses were ¥921 million and the operating loss narrowed year on year. - FY2020-Q1MitigatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and R&D expenses related to the precision oncology business. The consolidated operating loss was ¥617 million (loss of ¥712 million in the previous period).」
R&D and clinical development expenses continued to be incurred, while the increase in operating revenue, decrease in R&D expenses and year-on-year narrowing of the operating loss were reported. - FY2019-Q3MitigatedAnnual report
「Consolidated operating revenue for the first 3 quarters of the current consolidated cumulative period was ¥247 million, due to milestone payments from partner pharmaceutical companies and income from contract testing services, among other sources, an increase of ¥44 million year on year. In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and R&D expenses related to the precision oncology business. The consolidated operating loss was ¥2,146 million (loss of ¥2,217 million in the previous period).」
R&D and clinical development expenses continued to be incurred, but operating revenue increased by ¥44 million year on year and the consolidated operating loss narrowed from ¥2,217 million to ¥2,146 million. - FY2019-Q2WorsenedAnnual report
「Consolidated operating revenue for the first half of the current consolidated cumulative period was ¥24 million, due to royalties from sales of research reagents and other sources and income from contract testing services, among other sources, a decrease of ¥176 million year on year. In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and R&D expenses related to the precision oncology business. The consolidated operating loss was ¥1,725 million (loss of ¥1,425 million in the previous period).」
R&D expenses increased from ¥1,489 million in the same period of the previous year to ¥1,598 million, and the operating loss widened from ¥1,425 million to ¥1,725 million. R&D expenses related to the precision oncology business continue to be explicitly identified as a factor contributing to the loss. - FY2019-Q1WorsenedAnnual report
「Consolidated operating revenue for the first quarter of the current consolidated cumulative period was ¥13 million, due to royalties from sales of research reagents and income from contract testing services, among other sources, a decrease of ¥187 million year on year. In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates, the main factors were expenses arising from progress in clinical development in 3 areas—small-molecule drugs, cancer peptide vaccines and antibody drugs—and R&D expenses related to the precision oncology business. The consolidated operating loss was ¥712 million (loss of ¥593 million in the previous period).」
In addition to R&D expenses and clinical development expenses in the 3 drug discovery areas, R&D expenses related to the precision oncology business were explicitly identified as a factor contributing to the loss. The operating loss widened from ¥593 million in the same period of the previous year to ¥712 million. - FY2018RestatedAnnual report
「As an R&D-oriented company, the group recorded ¥2,931 million in the fiscal year ended March 2018 and intends to continue pursuing clinical development proactively.」
R&D expenses were significant at ¥2,931 million, and loss pressure from the R&D-led business model continued. This was a slight decrease from ¥2,938 million in the previous fiscal year. - FY2018-Q3WorsenedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates and other compounds, the main factor was the recognition of expenses arising from progress in clinical development in 3 areas: small-molecule drugs, cancer-specific peptide vaccines and antibody drugs. The operating loss was ¥2,217 million (loss of ¥2,195 million in the same quarter of the previous year).」
R&D expenses and clinical development expenses in the 3 areas were the main causes of the operating loss, which widened by ¥22 million from the same quarter of the previous year. - FY2018-Q2RestatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates and other compounds, the main factor was the recognition of expenses arising from progress in clinical development in 3 areas: small-molecule drugs, cancer-specific peptide vaccines and antibody drugs. The operating loss was ¥1,425 million (loss of ¥1,519 million in the same quarter of the previous year).」
R&D expenses were ¥1,489 million, and expenses from the R&D- and clinical-development-led business model continued to be the main cause of the operating loss. The loss narrowed from the same quarter of the previous year. - FY2017WorsenedAnnual report
「In the fiscal year under review, ¥2,938 million was recorded, and the company intends to continue pursuing clinical development proactively.」
R&D expenses increased from ¥2,883 million in the previous fiscal year to ¥2,938 million, while the consolidated operating loss was ¥3,004 million. The company describes the cost and loss pressure from its R&D-led business model together with the figures. - FY2017-Q3RestatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates and other compounds, the main factor was the recognition of expenses arising from progress in clinical development, primarily in 3 areas: small-molecule drugs, cancer-specific peptide vaccines and antibody drugs. As a result, the operating loss was ¥2,195 million (operating loss of ¥2,269 million in the same quarter of the previous year), ordinary loss was ¥2,208 million (ordinary loss of ¥2,263 million), and quarterly net loss attributable to owners of the parent was ¥2,199 million (quarterly net loss attributable to owners of the parent of ¥2,123 million).」
The company continues to incur expenses associated with basic research, drug discovery research and clinical development in the 3 areas, which remain the main causes of the loss. - FY2017-Q2RestatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates and other compounds, the main factor was the recognition of expenses arising from progress in clinical development, primarily in 3 areas: small-molecule drugs, cancer-specific peptide vaccines and antibody drugs. As a result, the operating loss was ¥1,519 million (operating loss of ¥1,473 million in the same quarter of the previous year), ordinary loss was ¥1,502 million (ordinary loss of ¥1,469 million), and quarterly net loss attributable to owners of the parent was ¥1,497 million (quarterly net loss attributable to owners of the parent of ¥1,334 million).」
The company continues to explain that expenses associated with basic research, drug discovery research and clinical development in the 3 areas are the main causes of the loss. - FY2017-Q1RestatedAnnual report
「In addition to R&D expenses from the continued basic research and drug discovery research on drug candidates and other compounds, the main factor was the recognition of expenses arising from progress in clinical development, primarily in 3 areas: small-molecule drugs, cancer-specific peptide vaccines and antibody drugs. As a result, the operating loss was ¥783 million.」
The company continues to explain that expenses associated with R&D and clinical development are the main cause of the operating loss. - FY2016First statedAnnual report
「In the fiscal year ended March 2016, ¥2,883 million was recorded, and the company intends to continue pursuing clinical development proactively.」
R&D expenses of ¥2,883 million, an operating loss of ¥2,980 million and a net loss attributable to owners of the parent of ¥2,788 million were recorded. Significant expenditures are expected to remain necessary, including for pipeline expansion.